Merrion Pharmaceuticals Ltd., a Dublin, Ireland-based developer of oral-dosage forms of drugs with poor bioavailability, has cut its IPO price range from $10-$12 per share to $6-$7 per share. It still plans to offer four million American depository shares, and to trade on both the Nasdaq and IEX under ticker symbol MERR. Punk, Ziegel & Co. is serving as lead underwriter. Shareholders include Growcorp Ltd. and Elan Corp. www.merrionpharma.com
Nearly there!
We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case
it’s been delivered there.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.
Copyright PEI Media
Not for publication, email or dissemination
Share with other subscribers
Only logged in subscribers of this site will be able to access the shared article.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.